Search results for "Retinal Vein"
showing 6 items of 36 documents
Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.
2013
Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.
Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion
2011
Patricia Udaondo1,2, Salvador Garcia-Delpech1,3, David Salom1,3, Maria Garcia-Pous1,3, Manuel Diaz-Llopis1,31Nuevo Hospital Universitario y Politecnico La Fe, Valencia, Spain; 2University Cardenal Herrera CEU, Valencia, Spain; 3Faculty of Medicine, University of Valencia, Valencia, SpainPurpose: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen®) injection in the management of refractory macular edema secondary to branch retinal vein occlusion.Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib s…
Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment
2012
Abstract Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year followup. There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGF agents to treat this condition. A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmic history of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmic examination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudati…
Management of macular edema due to branch retinal vein occlusion with intravitreal injections of pegaptanib sodium
2009
Purpose To evaluate the efficacy of Pegaptanib Sodium as single therapy for macular edema due to non-ischemic branch retinal vein occlusion. Methods In this uncontrolled prospective pilot study 17 patients have been included with non-ischemic branch retinal vein occlusion. All of them showed macular edema in the OCT with central foveal thickness higher than 350 microns (mean, 541 +/- 140) and decrease in visual acuity lower than 0,5 Snellen ETDRS charts notation (mean, 0,16+/-0,14). After an initial injection of Pegaptanib Sodium evaluations were programmed every 5 weeks and further retreatments were developed in cases with macular thickness higher than 300 microns. No other therapies were …
Vision-related function in the COPERNICUS and GALILEO trials
2014
Purpose To examine the impact of intravitreal aflibercept (IVT-AFL) injection on the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ) in the COPERNICUS and GALILEO trials. Methods Patients (pts) with macular oedema secondary to central retinal vein occlusion received IVT-AFL 2 mg (IVT-AFL 2q4) or sham monthly for 24 weeks. After Week 24 (W24) in COPERNICUS all pts were eligible to receive IVT-AFL based on visual and anatomical outcomes (IVT-AFL 2q4+PRN, sham+IVT-AFL PRN). In GALILEO, sham-treated pts received sham tx until W52. The NEI VFQ was administered at baseline (BL), W24 and W52. Total and subscale scores were compared between groups. W24 data were integrated an…
Optical quality of hyperopic and myopic phakic intraocular lenses
2013
Aims: To assess and compare the optical quality of the myopic and hyperopic implantable collamer lens (ICL) from its wavefront aberrations for different powers and pupil diameters. Settings and Design: Prospective study. Material and Methods: The wavefront aberrations of two myopic (−3 and −6 diopters (D)) and two hyperopic V4b ICLs (+3 and +6D) were measured in vitro . To assess and compare the optical quality of different powers of ICLs, we analyzed the root mean square (RMS) of total higher order aberrations (HOAs), trefoil, coma, tetrafoil, secondary astigmatism, and spherical aberration at 3- and 4.5-mm pupil. In addition, the point spread functions (PSFs) of each ICL evaluated were ca…